Announcement

Collapse
No announcement yet.

J Infect. Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19.

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • J Infect. Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19.


    J Infect. 2020 Apr 10. pii: S0163-4453(20)30188-2. doi: 10.1016/j.jinf.2020.03.060. [Epub ahead of print]
    Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19.


    Zhu Z1, Lu Z2, Xu T3, Chen C4, Yang G2, Zha T5, Jianchun6, Xue Y7.

    Author information




    Abstract

    Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.
    Copyright ? 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.



    KEYWORDS:

    COVID-19; Ct value; SARS-CoV2; antiviral therapy; pneumonia


    PMID:32283143DOI:10.1016/j.jinf.2020.03.060

Working...
X